NYU study: Alzheimer’s protein protects metastasized melanoma cells in the brain

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Researchers from NYU Grossman School of Medicine and NYU’s Laura and Isaac Perlmutter Cancer Center found that amyloid beta, a protein known to build-up in the brains of Alzheimer’s patients, helps melanoma cells thrive when they have spread to the brain. The study authors focused on melanoma because it metastasizes to the brain in 40% of patients with stage IV disease.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


Iovance Biotherapeutics Inc. a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte therapies for patients with cancer, has updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, for the upcoming 2024 ASCO Annual Meeting.